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Since their discovery in the end of the 1960s and the
beginningofthe1970sbyAlexanderFriedenstein,mesenchy-
mal stromal cells (MSCs) have attracted the interest of the
scientiﬁc community because of their ubiquitous presence in
the organism, the ease of their procurement, and potential
to diﬀerentiate into other tissues. As a nonhematopoietic
cell population, ﬁrst described in the bone marrow, MSCs
comprise a pool of progenitor cells with diﬀerent prolifera-
tive, diﬀerentiation, immunosuppressive, and hematopoietic
engraftment-promoting potential. To bring more insights
into cellular and molecular mechanisms of action of MSCs
and their potential for clinical use, stem cells international
set out to launch and publish a special Issue on this topic.
In this issue, distinguished researchers from all over the
world contributed with their experience and knowledge to
highlight the latest developments in this emerging ﬁeld of
research.
The conundrum of the MSC origin remains unresolved
due to the lack of a speciﬁc cell surface marker. Identiﬁcation
of such markers could undoubtedly help the scientists to
develop new methodologies for prospective isolation and
expansion of MSCs in their “native” state (undiﬀerentiated)
for clinical application.
S. A. E. Boxall and Jones in the UK (in “Markers for char-
acterization of bone marrow multipotential stromal cells”)
have focused on description of the most important markers,
which have been reported so far for the characterization and
prospective isolation of progenitor cells for MSCs. In the
ﬁrst part of this paper, the authors discussed surface and
molecular markers that were proposed as the indicators of
MSC potency, in terms of their proliferative potential or the
ability to diﬀerentiate into desired lineages. In the second
part of this paper, the authors discussed critically surface
markers of uncultured (i.e., native) bone marrow-(BM-)
derived MSCs. Although no formal consensus has yet been
reached on which markers may be best suited for prospective
BM-MSC isolation, the authors suggest that markers that
cross-react with MSCs of animal models (such as CD271 and
W8-B2/MSCA-1) may have the strongest translational value.
As the number of progenitor cells for MSCs in BM
and other organs is pretty low, MSCs should be ex vivo
expanded in order to achieve a suﬃcient number for clinical
application. Historically, large-scale clinical expansions of
MSCs have been performed by using a basal medium sup-
plemented with fetal bovine serum (FBS). Because of the ill-
deﬁned nature of FBS (presence of xenogeneic components)
and lot-to-lot inconsistency of performance, development
of a more deﬁned serum-free MSC culture medium has
become absolutely necessary. Therefore, S. Jung et al. in
Canada (in “Ex vivo expansion of human mesenchymal
stem cells in deﬁned serum-free media”) reviewed herein
current cell culture media for hMSCs and discussed medium2 Stem Cells International
development strategies. In addition to the serum-containing
and serum-free MSC-culture medium supplemented with
platelet lysates the authors compared properties of a serum-
free, chemically deﬁned MSC-culture medium (PPRF-msc6)
developedintheirlaboratorywiththecommerciallyavailable
serum-free media.
MSCs after their in vivo administration show their anti-
inﬂammatory and regenerative eﬀects either by secretion
of long-distance acting soluble molecules or by migrating
and homing to the damaged tissues. S. k. Kang et al. in
South Korea in their review (in “Journey of mesenchymal
stem cells for homing: strategies to enhance eﬃcacy and safety
of stem cell therapy”) outline the current understanding of
MSC migration and discuss strategies for enhancing both
the environmental and cellular conditions that give rise to
eﬀectivehomingofMSCs.Accordingtotheauthors,thismay
allow MSCs to quickly ﬁnd and migrate to injured tissues,
where they may best exert clinical beneﬁts resulting from
improved homing and the presence of increased numbers of
MSCs.
Extensive experimental research during the past decades
profoundly inﬂuenced the understanding of the mechanism
of MSC-action and consequently its potential use in regen-
erative medicine. P. Babei et al. in Iran (in “Transplanted
bone marrow mesenchymal stem cells improve memory in rat
models of alzheimer’s disease”) demonstrated in the rat model
that MSC treatment signiﬁcantly increased learning ability
and memory in both age-induced and chemically induced
memory impairment.
In addition, stem cell-based therapy represents a rapidly
growing alternative for cardiovascular diseases as the leading
cause of death worldwide. M. T. Elnakish et al. in USA (in
“Mesenchymal stem cells for cardiac regeneration: translation
to bedside reality”) focussed on therapeutic applications of
MSCs and their transition from experimental bench side to
clinical bedside. Based on the reports published so far, they
conclude that in addition to embryonic stem cells, induced
pluripotent stem cells (iPSCs), endothelial progenitor cells,
hematopoietic stem cells, and skeletal myoblasts that were
used in the treatment of ischemic heart disease and myocar-
dial infarction, MSCs due to their distinctive properties
represent an innovative approach for cardiac regeneration.
In line with this, N. A. Kouris et al. in USA (in “Directed
fusion of mesenchymal stem cells with cardiomyocytes via
VSV-G facilitates stem cell programming”) in their original
article demonstrated that expression of the fusogen of
the vesicular stomatitis virus (VSV-G) in human MSCs
(vMSCs)increasedtheirfusioncapacitywithcardiomyocytes
(CMs). The fused cells adopted a CM-like phenotype and
morphology in vitro. Furthermore, the authors found that
the vMSCs delivered to the damaged mouse myocardium,
via a collagen patch, were able to home to the myocardium
and fuse to cells within the infarct and peri-infarct region of
the myocardium and exerted functional beneﬁt via multiple
mechanisms.
H. Thaker and A. K. Sharma in USA (in “Engaging stem
cells for customized tendon regeneration”) outlined in their
review the use of MSCs together with poly(1,8-octanediol
co-citrate) scaﬀolds(POCs)todevelopaﬁbroelasticnetwork
guided bycytokines and growth factorsin order to be used as
a consistent therapeutic approach to tendon injury repair.
R. Nuzzi et al. in Italy (in “Eﬀect of in vitro exposure of
corticosteroid drugs, conventionally used in AMD treatment,
on mesenchymal stem cells”) in their research article found
that steroid drugs, often used to treat age-related macular
degeneration(AMD),demonstrateanegativeeﬀectonMSCs
as a potential candidate for treatment of AMD. This eﬀect
was reduced in the presence of supernatant of a human
retinal pigment epithelial cell line (ARPE-19).
As MSCs exert a very potent immunomodulatory eﬀect,
they are often used clinically to suppress the adverse eﬀects
of graftversus host disease (GvHD)afterhematopoietic stem
celltransplantation.Becauseofabroadimmunosuppression,
the patients are at risk of bacterial and viral infections. G.
Lucchini et al. in Italy (in “Mesenchymal stromal cells do not
increase the risk of viral reactivation nor the severity of viral
events in recipients of allogeneic stem cell transplantation”)
in their clinical study analyzed viral reactivation episodes
by a whole blood PCR in 24 patients receiving MSCs for
the treatment of GvHD. In their cohort of patients, viral
reactivation after MSC infusion occurred in 45% of the
cases, which did not signiﬁcantly diﬀer from the incidence
in a historical cohort of patients aﬀected by steroid-resistant
GvHD and treated with conventional immunosuppression.
In addition to the bone marrow, during the last decade
the adipose tissue is being recognized not only as an energy
reservoir, but also as a rich source of multipotent cells. P.
C. Baer and H. Geiger in Germany (in “Adipose-derived
mesenchymal stromal/stem cells: tissue localization, character-
ization, and heterogeneity”) and H. Orbay et al. in Japan
(in “Mesenchymal stem cells isolated from adipose and other
tissues: basic biological properties and clinical applications”)
in their review articles made an overview about the sources
and methods of isolation, phenotype as well as the potential
of adipose tissue-derived MSCs to give rise to the tissues
of three germ layers. In line with this, R. k. Chan et al.
in USA (in “Development of a vascularized skin construct
using adipose-derived stem cells from debrided burned skin”)
have exploited autologous stem cells from the adipose layer
of surgically debrided burned skin (dsASC) to generate in
vitro an epithelial layer, a vascularised dermal layer, and a
hypodermal layer. The authors conclude that this technique
may provide an alternative approach for cutaneous coverage
after extensive burn injuries.
Regulatory issues concerning the safety of clinical use of
MSCs are strongly required for their broad clinical appli-
cation. Y. Wang et al. in China (in “Safety of mesenchymal
stem cells for clinical application”) in their review focussed
on safety issues of MSCs, in particular their genetic stability
in long-term in vitro expansion, their cryopreservation,
banking, and the role of serum in the preparation of
MSCs. Based on hundreds of clinical trials using MSCs
that have been registered, the authors conclude that the
production of safe cell products requires an entire process of
supervision in order to assure that the cells maintain overall
phenotype, functional potential, and to ensure that cultured
cells remain untransformed and without microbiological
contaminations.Stem Cells International 3
In summary, we hope that the reader of this special issue
willgainmoreinsightsintotheadvancementsandchallenges
faced by this rapidly expanding ﬁeld of medicine.
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